Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75 mg twice daily administration

Journal of Pharmaceutical Health Care and Sciences
Yuuki AkagiKaoru Sugi

Abstract

Dabigatran is a direct thrombin inhibitor and an anticoagulant that is prescribed to prevent ischemic stroke and systemic embolism in non-valvular atrial fibrillation. Dabigatran (150 mg twice daily) is non-inferior to warfarin for the prevention of stroke and systemic embolism. A dose reduction to 110 mg twice daily should be considered for patients with decreased renal function, elderly patients, and those with a history of gastrointestinal bleeding. A small number of patients are prescribed 75 mg twice daily; however, excessive dose reduction below that indicated on the package insert may decrease the effectiveness of dabigatran. In this study, we investigated the incidence of thromboembolic events and hemorrhagic complications in patients receiving different doses of dabigatran, including patients receiving the very low-dose of 75 mg twice daily. Five hospitals in Meguro and Setagaya areas of Tokyo were included in this study. The subjects were patients receiving dabigatran in the hospitals from March 2011 to February 2014. Thromboembolic events (stroke, systemic embolism, and transient cerebral ischemic attack) and hemorrhagic complications occurring before December 2014 were retrospectively evaluated. A total of 701 subje...Continue Reading

References

Feb 18, 2005·Journal of Neurology, Neurosurgery, and Psychiatry·J HataM Iida
Oct 3, 2006·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Mayumi IshizukaShoichi Fujita
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Apr 9, 2013·Journal of the American College of Cardiology·Torben Bjerregaard LarsenGregory Y H Lip
Jun 8, 2013·Stroke; a Journal of Cerebral Circulation·Masatsugu HoriUNKNOWN RE-LY Investigators
Jun 14, 2014·The American Journal of Cardiology·Koji GotoUNKNOWN CREDO-Kyoto Registry Cohort-2 Investigators
Jun 27, 2014·Circulation Journal : Official Journal of the Japanese Circulation Society·UNKNOWN JCS Joint Working Group
Dec 19, 2017·Journal of Atrial Fibrillation·Katy LavoieMarie-France Beauchesne

❮ Previous
Next ❯

Citations

Jan 12, 2020·Journal of Basic and Clinical Physiology and Pharmacology·I Nyoman WijayaAndi Hermansyah

❮ Previous
Next ❯

Software Mentioned

JMP Pro

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.